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Abstract
Background: MicroRNAs (miRNAs) are short endogenous, single-stranded, noncoding small RNA molecules of
approximately 22 nucleotides in length. They regulate gene expression posttranscriptionally by silencing mRNA
expression, thus orchestrating many physiological processes. The Small Ruminant Lentiviruses (SRLV) group includes
the Visna Maedi Virus (VMV) and Caprine Arthritis Encephalitis (CAEV) viruses, which cause a disease in sheep and
goats characterized by pneumonia, mastitis, arthritis and encephalitis. Their main target cells are from the monocyte/
macrophage lineage. To date, there are no studies on the role of miRNAs in this viral disease.
Results: Using RNA-seq technology and bioinformatics analysis, the expression levels of miRNAs during
different clinical stages of infection were studied. A total of 212 miRNAs were identified, of which 46 were
conserved sequences in other species but found for the first time in sheep, and 12 were completely novel.
Differential expression analysis comparing the uninfected and seropositive groups showed changes in several
miRNAs; however, no significant differences were detected between seropositive asymptomatic and diseased
sheep. The robust increase in the expression level of oar-miR-21 is consistent with its increased expression in
other viral diseases. Furthermore, the target prediction of the dysregulated miRNAs revealed that they control
genes involved in proliferation-related signalling pathways, such as the PI3K-Akt, AMPK and ErbB pathways.
Conclusions: To the best of our knowledge, this is the first study reporting miRNA profiling in sheep in
response to SRLV infection. The known functions of oar-miR-21 as a regulator of inflammation and
proliferation appear to be a possible cause of the lesions caused in the sheep’s lungs. This miRNA could be
an indicator for the severity of the lung lesions, or a putative target for therapeutic intervention.
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Background
The Small Ruminant Lentiviruses (SRLVs) are in a group
of RNA viruses in the lentivirus genus that infect cells of
the monocyte/macrophage lineage from sheep and goats.
This infection causes progressive inflammatory lesions in
the lungs, brain, mammary glands and joints that are char-
acterized by lymphoid hyperplasia, interstitial infiltration
of mononuclear cells and interstitial pneumonia. Visna/
Maedi disease (VM) has a great economic importance
derived from decreased animal production and increased
replacement rates [1]. Infection is present in most coun-
tries that raise sheep but the impact on production and
animal welfare is affected by breed [2] and flock manage-
ment [3].
Not every infected animal shows the disease due to
the importance of the host genetic background [4]. In
genetic association studies several molecules have been
shown to be related to VMV infection: Toll like recep-
tors (TLRs), antiviral proteins (APOBEC family, TRI-
M5alpha, tetherin), and cytokines (among others) [5, 6].
To our knowledge, microRNAs (miRNAs) have not been
analyzed in relation to this viral disease.
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miRNAs are a class of noncoding endogenous RNAs
of approximately 22 nucleotides that regulate gene ex-
pression posttranscriptionally. By binding to mRNA
molecules and with the help of the RNA-induced silen-
cing complex (RISC), they can silence or cleave mRNA
molecules [7]. They are one of the most abundant gene
expression regulators and have an effect on phenotypic
variations in domestic animals [8]. Several studies have
identified miRNAs in various sheep breeds, although
miRBase 21 includes only 106 miRNA precursors and
153 mature sequences (January 2018). Regarding tissue
types that have been previously studied, most of the
work has focused on muscle quantity, wool quality, fer-
tility and fat deposition [9–12] with little attention to
animal health and welfare.
Viruses exploit host gene pathways to accomplish
their basic biological processes, from transcription to
protein synthesis, thus, ensuring their own survival.
MicroRNA levels can be altered due to the host’s
own immune response modulation [13]; however, vi-
ruses can also modulate the expression of host genes
to avoid detection by the immune system or to mod-
ify cell survival pathways [14]. Furthermore, it has
been proposed that host miRNAs can directly target
RNA viruses either cleaving them or stabilizing them
[15]. Another way that miRNA expression may
change involves virally encoded miRNAs [16].
The aim of this study was to uncover the host mech-
anisms that are associated with VM disease in sheep.
To this end, the cellular miRNAs differentially
expressed at different stages of infection were identi-
fied, and information about involved genes, the mech-
anisms, and relevant pathways was inferred via
bioinformatics analyses. These predictions could also
contribute to uncover the roles of miRNAs in
host-virus interactions.
Methods
Animals
Thirty Rasa Aragonesa adult (3 to 6 years) ewes were
included in this study, in different stages of a natural
infection of VMV. The samples were obtained from
different commercial flocks in the routine of the Vet-
erinary Faculty (University of Zaragoza) in the frame-
work of the national research project ref. AGL2010–
22341-C04–01. The complete experimental procedure
was approved and licensed by the Ethical Committee
of the University of Zaragoza (ref: PI09/10). Animals
were euthanized by an intravenous injection of a bar-
biturate overdose (Dolethal®, Vetoquinol, Spain) and
exsanguinated.
Animals were classified attending to their VMV
infection status (seronegative or seropositive) using an
Enzyme-Linked ImmunoSorbent Assay (ELISA) (ELIT
EST, Hyphen), and the clinical outcome (asymptom-
atic and diseased). For RNA-seq analysis, a total of 15
animals were included: Five animals were seronegative
for VMV (seronegative group), five of the animals
tested seropositive for VMV but did not show clinical
symptoms (seropositive asymptomatic group) and, the
remaining five animals were seropositive and had lung
lesions (lesions group). For validation of the sequen-
cing data 15 different animals were included (5 sero-
negative, 5 seropositive asymptomatic and 5 with
pulmonary lesions) (Table 1).
Tissue collection, RNA extraction and small RNA
sequencing
A sample from lung was aseptically taken from each ani-
mal and preserved in RNAlater solution (Ambion, Aus-
tin, TX, USA) at −80 °C until used. Total RNA was
isolated from lung tissue using Trizol (Invitrogen, Carls-
bad, CA, USA) extraction. 60–70 mg tissue samples were
homogenized in 1 ml of Trizol using Precellys®24
homogenizer (Bertin Technologies, Montigny le Breton-
neux, France) combined with 1.4 and 2.8 mm ceramic
beads mix lysing tubes (Bertin Technologies). After add-
ing chloroform, RNA was precipitated from the upper
aqueous phase with isopropanol, washed with ethanol,
suspended in RNase free water and stored at − 80 °C.
RNA quantity and purity was assessed with NanoDrop
1000 Spectrophotometer (Thermo Scientific Inc., Bre-
men, Germany). RNA integrity and concentration was
assessed with the 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA).
The small RNA libraries were generated with Illumi-
na’s TruSeq small RNA library preparation kit following
manufacturer’s instructions. Sequencing was performed
in CNAG-CRG core facility (Barcelona, Spain), using an
Illumina HiSeq 2500 instrument. Single-end sequencing
with 50 bp read length was used for miRNAs.
Table 1 Samples used in RNA-seq and RT-qPCR study
RNA-seq
Status Animals (15)
Pulmonary lesions 1P, 2P, 7P, 9P, 10P
Seropositive asymptomatic 8P, 11P, 12P, P19, 4
Seronegative 7,10,11, 13,14
RT-qPCR
Status Animals (15)
Pulmonary lesions P21, P22, P24, P25,P26
Seropositive asymptomatic 1, 2, 3, 5, 6
Seronegative 12, P-13, P-14, P-15, P-16
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Prediction of miRNAs
The quality control was performed with fastQC and the
following computational pipeline was followed (Fig. 1).
Raw reads were analyzed with the sRNAbench web tool,
which is included in the sRNAtoolbox collection of tools
[17]. This program performed the preprocessing, map-
ping, expression profiling and novel miRNA prediction.
Parameters were set to minimum read count of four,
allowing one mismatch, with full read alignment and
three species were selected to search for homologs: goat,
cattle and mouse. After that, the prediction results of
novel miRNAs were manually curated to remove re-
peated entries that just differed in one nucleotide and to
give more updated miRNA names. Only miRNAs
marked with high confidence by the program were se-
lected for further analysis. Since the program only uses
miRNAs present in miRBase, new predicted miRNAs
that could had been previously described elsewhere were
locally blasted against the whole RNAcentral database
(http://rnacentral.org/) looking for perfect identity.
Differential expression
Before the differential expression analysis, the matrix of
novel miRNAs was built excluding repeated miRNAs
that mapped in different places, miRNAs that appeared
in less than half of the samples and with counts lower
than ten. This was done following common criteria in the
field to perform a conservative analysis. In addition, it was
performed a principal component analysis (PCA) (Add-
itional file 1) to check the grouping of the samples with
the DESeq2 Bioconductor R package (https://bioconduc-
tor.org/packages/release/bioc/html/DESeq2.html). Three
out of the 15 samples were excluded from further
analysis - these outliers highly increased variability -
leaving three groups with four samples each. DESeq2
results were plotted out as a heatmap with the Pheat-
map function for R (https://cran.r-project.org/packa-
ge=pheatmap). Differential expression analysis of
both, known and novel miRNAs was performed with
the sRNAde web tool included in the sRNAtoolbox
collection [17]. DESeq2 and EdgeR were the methods
Fig. 1 Computational pipeline of data analysis. The figure illustrates the four steps of the data analysis starting from the RNA extraction and
sequencing: miRNA detection and prediction, differential expression, target prediction and functional analysis
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used by the program. Three different comparisons
were performed: Asymptomatic vs Seronegative, Le-
sions vs Seronegative and Lesions vs Asymptomatic.
For a miRNA to be considered differentially expressed
(DE), the adjusted p value was set to 0.05 and the ab-
solute log2 expression fold change (FC) to one.
Target prediction, gene ontology and pathway analysis
Target genes for each differentially expressed miRNA were
predicted using TargetScan 7 [18] and miRanda – via the
miRNAconstarget tool included in sRNAtoolbox [17] – al-
gorithms. The 3’ UTR mRNA sequences of sheep for both
programs were obtained from the multi-species alignment
generated from human 3’ UTRs given by the authors of
TargetScan. The threshold for this program was set to ab-
solute context++ score > 1 and the thresholds for miRanda
were set to a score higher than 155 and a free energy
lower than -20 kcal/mol. The consensus targets predicted
by both programs were selected.
Viral-targeting miRNAs in the ovine genome were also
inferred by using 11 VMV (Visna Maedi Virus) and 5
Caprine Arthritis Encephalitis Virus (CAEV) complete
sequences deposited in GenBank database. The program
used was standalone miRanda [19].
In order to obtain biological information from the tar-
get genes of differentially expressed miRNAs, an enrich-
ment analysis was performed. We built three sets of
genes that interacted in our predictions with any of the
DE miRNAs in each comparison. Pathway and gene
ontology (GO) analysis were carried out with David
(https://david.ncifcrf.gov/) web tool. For pathways,
KEGG pathway terms were tested and Benjamini mul-
tiple test correction value of 0.05 was applied as a
threshold. We used Cytoscape version 3.5.1 [20] to build
functional networks merging interactions among miR-
NAs, target genes and enriched pathways. This way, we
were able to visualise genes in the selected pathways that
are being targeted by dysregulated miRNAs.
RT-qPCR validation
To validate changes identified by RNA-seq experiment,
the relative expression levels of 7 miRNAs (oar-miR-125b,
oar-let-7b, oar-miR-181a, oar-miR-148a, oar-miR-21,
oar-miR-30c, oar-miR-379-5p) selected based on signifi-
cant changes seen in Lesions vs Seronegative comparison
in the RNA-seq analysis, were verified by qPCR. The U6
snRNA, oar-miR-30d and oar-miR-191 were tested as in-
ternal standard controls and the last two were selected for
their expression stability in our samples. Additional file 2
shows the list of the amplified miRNAs and the corre-
sponding primer sequences. The expression study has
been based on the analysis of miRNA expression with Flu-
digm’s BioMark HD Nanofluidic qPCR System technology
combined with GE 48.48 Dynamic Arrays IFC. qPCR was
performed on a BioMark HD System using Master Mix
SsoFastTM EvaGreen® Supermix with Low ROX (Bio-Rad
Laboratories, Hercules, CA, USA). The analysis of expres-
sion with the Fluidigm Biomark HD Nanofluidic qPCR
system was performed at the Gene Expression Unit of the
Genomics Facility, in the General Research Services (SGI-
KER) of the UPV/EHU.
The software for the real-time PCR analysis and obtain-
ing of the Ct values was Fluidigm Real-Time PCR Analysis
Software [v3.1.3]. PCR efficiency calculation and correc-
tion, reference miRNA stability analysis and normalization
was done with GenEx software of MultiD [v5.4]. Most
miRNAs showed high amplification efficiencies (94.43–
99.65%). The stability of candidate reference miRNAs was
analyzed using both NormFinder [21] and GeNorm [22]
algorithms integrated in GenEx. The two most stable miR-
NAs were oar-miR-30d and oar-miR-191 so normalization
was performed using these two reference miRNAs. Nor-
mal distribution was checked using the Shapiro-Wilk test
in the IBM SPSS statistical package [v24]. Comparison
and correlation between the RNA-seq and qPCR results
was performed using T-test and Pearson’s correlation, re-
spectively. In all analyses, differences were considered sig-
nificant when p values were < 0.05.
Results
Small RNA sequencing and miRNA prediction
In the present study, the small RNAs from lung tissue of
sheep with and without VMV infection were sequenced.
The raw reads were high quality – only approximately
2% had Q scores below 30 – and the numbers of reads
ranged from 22 to 8 million, with an average of 15 mil-
lion reads. The raw reads were analyzed by sRNAbench
for miRNA prediction, trimmed the adapters in around
the 95% of the reads in all the samples, and 85% of the
preprocessed reads were successfully mapped to the
sheep genome. The read-length distribution showed a
clear peak between 21 and 23 nucleotides in all of the
samples, where most of the reads were located.
Out of the mapping, the program could annotate 86
known sheep miRNAs from miRBase. All of the other
reads that mapped to the genome, but that did not coin-
cide with a miRBase miRNA were subjected to novel
discovery tests, from which several new miRNAs arose.
Some of these new miRNAs were apparently completely
novel molecules, and others were found to be conserved
in other species. After cleaning the output sequences
and aligning them with RNAcentral, it was found that
some were already annotated in sheep and that others
had homologs in other species. In total, 86 known miR-
NAs from miRBase, 68 known sheep miRNAs from
other databases, and 58 miRNAs shown for the first time
in sheep were found (Fig. 2b). Twelve miRNAs out of
these 58 could not be considered ovine homologs of
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previously described miRNAs and were considered
novel. The full list of the described miRNAs not present
in miRBase is in Additional file 3. The novel miRNAs
were named sequentially, but they were given the name
of a homolog if one existed. Regarding the expression
levels, some miRNAs were much more abundant than
others (Fig. 2a): the 13% most abundant miRNAs were
above 10,000 counts, while the 29% least abundant miR-
NAs had fewer than five average counts. Furthermore,
the miRNAs classified as novel or conserved had par-
ticularly low abundance, with only few of them having
more than 1000 counts.
Differentially expressed miRNAs
We made pairwise comparisons among the three sample
groups. Overall, the differential expression levels, as well as
the PCA, pointed out that the biggest differences were be-
tween seronegative sheep and the other two seropositive
groups (asymptomatic animals and animals with Lesions).
Clustering of differentially expressed (DE) miRNAs de-
tected by either of the two programs clearly grouped the
seronegative samples, but failed to distinguish the other
two groups, similar to the outcome of the PCA. Seroposi-
tive asymptomatic animals and animals with developed
clinical symptoms seemed quite similar in terms of miRNA
expression (Fig. 3; Additional file 1). By merging the results
of the EdgeR and DESeq2 analyses, 34 DE miRNAs were
identified between clinically affected and seronegative
sheep, of which 23 were upregulated and 11 downregulated.
There were also 9 upregulated and one downregulated
miRNAs when comparing samples from seropositive
asymptomatic animals with samples from seronegative ani-
mals, and only three miRNAs were differentially expressed
between animals with clinical symptoms and seropositive
asymptomatic animals (Table 2). Some novel ovine miR-
NAs with homologs in other mammals, namely,
chi-miR-30f-5p, chi-miR-449a-5p, mmu-let-7e-3p, mmu-
miR-144-3p, bta-miR-142-5p, chi-mir-92a-3p, ssc-mir-
7134-3p, ssc-mir-7134-5p and mmu-miR-98-5p, from goat
(chi), mouse (mmu), pig (ssc) and cattle (bta), showed dif-
ferences in VMV infected animals. Completely novel miR-
NAs did not differ significantly in their expression likely
due to their low expression levels, which were sometimes
even below the applied count threshold.
Among the most abundantly expressed DE miRNAs,
some showed relevant increases or reductions in expres-
sion (Fig. 4): oar-miR-21 was, by far, the most abundant
DE miRNA, since its expression was elevated 4.3 times
in seropositive asymptomatic animals and 12 times in
diseased animals, with average total counts of around
two million. Other highly expressed DE miRNAs, such
as oar-miR-148a and oar-let-7f showed significant in-
creases, with absolute fold changes of 3 and 2.2, respect-
ively, in infected animals compared with seronegative
animals. Furthermore, miRNAs such as oar-let-7b,
oar-miR-99a and oar-miR-125b, showed reduced expres-
sion in infected sheep (Fig. 4).
Validation of differential miRNA expression
To validate the miRNA-seq data, seven miRNAs
(oar-miR-125b, oar-let-7b, oar-miR-181a, oar-miR-1
48a, oar-miR-21, oar-miR-30c, and oar-miR-379-5p)
were verified using the Fluidigm Biomark HD Nano-
fluidic qPCR system. The log2FC in the miRNA ex-
pression levels calculated by qPCR in the Lesions
group relative to the Seronegative group are shown in
Fig. 5. The validation results confirmed the upregu-
lated expression of 3 miRNAs (oar-miR-148a,
oar-miR-21, oar-miR-379-5p) and the downregulated
expression of 4 miRNAs (oar-miR-125b, oar-let-7b,
oar-miR-181a, and oar-miR-30c), although only two
were statistically significant: oar-miR-21 (p = 0.003)
and oar-miR-30c (p = 0.004). There were no signifi-
cant differences in the FC data obtained from the
a b
Fig. 2 Statistics of RNA-seq and prediction data. a Average counts distribution of all the miRNAs detected and predicted. b Distribution of
miRNAs according to previous knowledge about them
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RNA-seq and the Fluidigm Biomark HD Nanofluidic
qPCR system (p = 0.656) showing a high degree of
concordance, with a correlation coefficient of 0.982
(p = 0.000).
Functional analysis of dysregulated miRNAs
In this study, the targets of the DE miRNAs were predicted
using the TargetScan and Miranda algorithms. TargetScan
predicted a total of 1.9 million interactions for all of the
identified miRNAs, and this number was reduced to
124,614 after applying the cut-off value. Miranda predicted
911,069 target sites for the same set of miRNAs and appli-
cation of the threshold settings reduced this number to
41,871 targets. Next, we performed an intersection analysis
to enhance the confidence of the predictions, and this
process reduced the number of interactions to 12,280, with
6426 unique genes. An average of 35 interactions was ob-
served for each of the 349 mature miRNAs analyzed. Out
of the collection of the predicted targets, we retrieved three
sets of genes (one for each comparison) with 1736, 1135
and 190 genes each. These gene sets were then used in en-
richment analyses.
The GO enrichment analysis did not identify any
significantly enriched terms using the multiple testing
correction, whereas some pathways were actually over-
represented, such as, signalling pathways (e.g. PI3K-Akt,
AMPK and ErbB), or other terms such as ECM-receptor
interaction and pathways in cancer (Table 3). The
PI3K-Akt signalling pathway had the most genes
involved in both comparisons – 51 and 40, respectively
– and it was the most statistically significant term (cor-
rected P values of 2.51E-04 and 0.004). The comparisons
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Fig. 3 Hierarchical clustering heatmap. Clustering of all the DE miRNAs detected by any of both programs (DESeq2 or EdgeR) and samples.
Colours and intensities depend on expression level. Green indicates gene down-regulation and red up-regulation
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between the seropositive and seronegative sheep were
the only ones yielding results, while there were no
enriched terms in the comparison between the seroposi-
tive groups, based on the corrected p values.
Interaction maps incorporating the miRNAs and their
targets and the pathways information were produced in
an attempt to unveil how the differences in miRNA ex-
pression could affect these pathways in seropositive
asymptomatic compared to seronegative animals (Fig. 6)
and in diseased animals compared to seronegative ani-
mals (Fig. 7). Key regulators in the PI3K-Akt pathway,
such as PTEN, and related transcription factors such as
FOXO3 and CREB1, appear to be targeted by dysregu-
lated miRNAs identified between the seropositive groups
and the seronegative group. Most of the miRNAs target
no more than three genes in these pathways, except for
oar-miR-143 and oar-mir-361-3p, which target several
genes based on our predictions.
Virus-miRNA interactions
Regarding the highly expressed DE miRNAs, two signifi-
cantly strong interactions were found between the miR-
NAs and the SRLV genome. The upregulated miRNA
oar-miR-200a was predicted to target nine out the eleven
tested sequences at nucleotides 1671 to 1689 with re-
spect to the VMV reference genome sequence (GenBank
accession number L06906.1), with a score of 155 and a
folding energy of − 16.1 kcal/mol. The downregulated
miRNA oar-miR-99a was predicted to target nine se-
quences around nucleotides 5383 to 5402 with a score
of 150 and a folding energy of − 25.54 kcal/mol. These
predicted interactions are in the “gag” and “vif” genes,
respectively. These targeted sequences are all from the
genotype A of SRLV. On the other hand, oar-miR-99a
Table 2 Differential expression results of the three comparisons.
Only detections by both programs are showed and for the
selection, the adjusted p values of each program were used.
Log2 FC of 7.000 in DESeq2 means that the miRNA was present
in one group of samples but not in the other
miRNA Name DESeq2 EdgeR
Log2FC Padj Log2FC FDR
Lesions-Seronegative
oar-mir-322-3p −2.830 0.003 −2.880 0.005
chi-miR-30f-5p −2.199 0.0001 −2.226 0.02
oar-mir-361-3p 7.000 5.64E-13 14.182 3.1E-09
oar-mir-361-5p 7.000 4.57E-17 13.137 3.11E-08
chi-miR-449a-5p 6.270 0.017 6.105 0.009
mmu-let-7e-3p −2.092 0.029 −2.149 0.008
mmu-miR-144-3p 2.824 0.002 2.792 0.0007
oar-mir-32-5p 3.939 3.45E-05 3.877 0.0001
oar-mir-340-5p 1.827 0.029 1.746 0.038
oar-mir-34-nvb-5p 1.575 0.002 1.500 0.003
bta-miR-142-5p 7.000 3E-10 12.956 3.79E-05
oar-mir-9/mir-79-nv1-5p 4.173 0.0002 4.045 0.043
chi-mir-92a-3p −1.559 0.0002 − 1.609 0.008
oar-mir-36-f-3p 7.000 2.84E-09 −14.383 3.84E-06
ssc-mir-7134-3p −3.517 0.0005 −3.676 0.009
ssc-mir-7134-5p −3.967 0.0002 − 3.968 4.45E-05
oar-let-7b −1.458 5.28E-05 −1.519 0.002
oar-let-7f 1.156 0.003 1.078 0.003
oar-miR-125b −2.083 2.65E-08 −2.134 3.84E-06
oar-miR-134-5p 3.267 0.026 3.184 0.002
oar-miR-136 2.623 0.047 2.529 0.003
oar-miR-148a 1.579 2E-05 1.501 1.93E-06
oar-miR-181a −1.781 1.16E-05 −1.836 6.47E-05
oar-miR-200a 1.614 0.001 1.533 0.008
oar-miR-21 3.584 2E-05 3.500 8.64E-16
oar-miR-299-3p 2.910 0.025 2.726 0.008
oar-miR-29b 2.156 0.01 2.087 0.016
oar-miR-30c −1.440 0.0002 −1.486 0.003
oar-miR-369-3p 2.966 0.043 2.858 0.002
oar-miR-376c-3p 2.268 0.022 2.158 0.002
oar-miR-376e-3p 2.058 0.032 1.975 0.006
oar-miR-379-5p 2.336 0.017 2.237 0.008
oar-miR-411a-5p 2.181 0.008 2.084 0.026
oar-miR-99a −1.117 0.002 −1.168 0.025
Seropositive asymptomatic-Seronegative
oar-mir-361-3p 7.000 7.11E-10 11.903 5.25E-07
oar-mir-361-5p 7.000 2.08E-17 13.286 6.77E-08
mmu-miR-144-3p 3.733 6.95E-05 3.690 8.51E-06
oar-mir-32-5p 3.679 0.0002 3.634 0.0005
Table 2 Differential expression results of the three comparisons.
Only detections by both programs are showed and for the
selection, the adjusted p values of each program were used.
Log2 FC of 7.000 in DESeq2 means that the miRNA was present
in one group of samples but not in the other (Continued)
miRNA Name DESeq2 EdgeR
Log2FC Padj Log2FC FDR
bta-miR-142-5p 7.000 2.42E-11 13.831 1.67E-05
mmu-miR-98-5p 5.023 0.0002 5.006 0.029
oar-let-7f 1.303 0.0007 1.237 0.0005
oar-miR-125b −1.361 0.0007 −1.401 0.008
oar-miR-148a 1.297 0.0009 1.224 0.0002
oar-miR-21 2.099 0.026 2.029 5.99E-06
Lesions-Seropositive asymptomatic
oar-mir-148/mir-152-5p −4.143 0.032 −4.098 0.005
oar-mir-36-f-3p 7.000 6.99E-08 −13.615 6.42E-05
ssc-mir-7134-5p −3.016 0.044 −2.973 0.009
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may also target CAEV at nucleotides 2194 to 2212 – in
the “pol” gene – with respect to the CAEV reference
genome (GenBank accession number M33677.1) with a
score of 160 and a folding energy of − 23.83 kcal/mol.
Discussion
In this work, we used NGS techniques to analyze the ex-
pression pattern of miRNAs in seronegative sheep and in
SRLV seropositive but asymptomatic animals and in dis-
eased animals. We then made predictions of the possible
regulatory functions of the miRNAs. Since we used tissue
samples from naturally infected animals for the experi-
ments, the data reflect the actual miRNA transcriptome in
the lung tissue of SRLV-infected animals. Host-virus inter-
actions modify several biological processes as a conse-
quence of the ability of the viruses to employ the host
machinery to complete their replication cycle, and of the
host’s attempts to deal with the infection. These changes
can be observed at the miRNA expression level since miR-
NAs can control different pathways; therefore,
Fig. 4 Expression of most abundant miRNAs. Average counts of the most expressed DE miRNAs in the three phases of disease progression.
Asterisks indicate significance level between two groups (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 5 qPCR validation of miRNAs. Expression of selected miRNAs in Lesions group relative to Seronegative group measured by RNA-seq and
qPCR. Bars represent the average results of the different samples. Statistically significant differences in the expression measured by qPCR of the
indicated miRNAs are showed with an asterisk (p < 0.05)
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Table 3 Enrichment analysis of pathways between both seropositive groups and the seronegative group. Significant entries with
Benjamini score equal or smaller than 0.05 are shown
Pathway Seropositive asymptomatic-Seronegative Lesions-Seronegative
Fold enrichment Benjamini Fold enrichment Benjamini
oas04151:PI3K-Akt signaling pathway 2.327 2,51E-04 1.868 0.004
oas04152:AMPK signaling pathway 2.831 0.024 2.411 0.022
oas05202:Transcriptional misregulation in cancer – – 2.111 0.024
oas05161:Hepatitis B 2.542 0.027 2.134 0.047
oas04012:ErbB signaling pathway 3.296 0.034 2.519 0.048
oas05200:Pathways in cancer – – 1.595 0.049
oas04512:ECM-receptor interaction 3.186 0.024 2.435 0.050
oas04510:Focal adhesion 2.232 0.029 – –
oas05215:Prostate cancer 3.296 0.034 – –
oas04360:Axon guidance 2.643 0.034 – –
oas04014:Ras signaling pathway 2.112 0.038 – –
oas05206:MicroRNAs in cancer 2.190 0.050 – –
Fig. 6 Functional network of the comparison between seropositive asymptomatic and seronegative sheep. It illustrates the predicted interactions
of DE miRNAs with their targets and the pathways those target genes are part of. Upregulated miRNAs are coloured in red and downregulated
ones in green, pathway names in orange and genes in blue
Bilbao-Arribas et al. BMC Genomics           (2019) 20:62 Page 9 of 13
understanding changes in miRNA expression could be
crucial for understanding the disease.
The enriched pathways identified in this study suggest
an increase in cell proliferation-related signaling. The
PI3K-Akt pathway is a key pathway involved in growth
and proliferation, and it has been extensively studied in
the context of proliferative diseases such as cancer; fur-
thermore, it seems to be influenced by a miRNA regula-
tory network as an added layer of modulation [23].
Furthermore, viruses can hijack this pathway for en-
hanced replication, as has been reported in several cases
[24]. For instance, Porcine Reproductive and Respiratory
Syndrome Virus (PRRSV) modulates PI3K-Akt signalling
via FoxO1 and Bad ([25]) and influenza A codes for the
NS1 protein which directly interacts with the PI3K regu-
latory subunit p85 ([26]). DE miRNAs were predicted to
target very important factors in this pathway including
PTEN, PI3K, FOXO3, the BCL2 family, CREB, GRB2,
growth factors (FGF23) and cytokine receptors
(IFNAR1). Other enriched pathways in our set of target
genes were the AMPK signalling pathway, which is a
regulator of cellular homeostasis and is linked to
PI3K-Akt pathway, and the ErbB pathway, which is re-
lated to signal transduction involving growth factors.
Although miRNAs are fine tuners of gene expression that
can act at low concentrations, the appearance of highly
expressed miRNAs may be very relevant and could indicate
strong modulation. Normally, a few miRNAs comprise the
majority of the miRNAome, and many others are present
at low concentrations. In our experiments, oar-miR-21 ex-
pression showed an interesting behaviour, as its expression
is remarkably high in both seropositive groups, with its
highest expression level in diseased animals. miR-21 is a
fairly well-studied miRNA, and was one of the first miR-
NAs identified as an oncogene; it has been seen to be up-
regulated in several conditions including tumours [27] and
viral infections. In the case of RNA viral diseases, miR-21 is
upregulated by hepatitis C virus (HCV), which leads to a
decreased IFN response in human cell lines [28], during
dengue virus infection in human cancer cells, which pro-
motes viral replication [29] and in HIV and in HIV-related
pulmonary arterial hypertension in human plasma [30].
Furthermore, Epstein-Barr virus (EBV) induces miR-21 ex-
pression in B cells, which promotes tumorigenesis by
Fig. 7 Functional network of the comparison between diseased and seronegative sheep. It illustrates the predicted interactions of DE miRNAs
with their targets and the pathways those target genes are part of. Upregulated miRNAs are coloured in red and downregulated ones in green,
pathway names in orange and genes in blue
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activating the PI3K-Akt pathway, causing FOXO3a to stop
repressing miR-21 [31, 32], findings that are in agreement
with our current results.
The respiratory form of SRLV infection exhibits some
typical histopathological lesions characterized by
lymphocytic infiltration and inflammation, M2-polarized
macrophages, interstitial pneumonia, lung fibrosis and
decreased gas exchange [33, 34]. However, the mecha-
nisms of this pathogenesis, which are likely immunome-
diated [35], are not fully characterized. There were no
major differences between the infected asymptomatic
animals and the sheep that did show lesions, indicating
that the miRNA levels mostly change after infection,
rather than when symptoms appear. It seems that most
of the transcriptional changes occur in the early stages
of infection and that the differences between the
asymptomatic-seronegative and the lesions-seronegative
comparisons could be due to disease progression and
appearance of clinical symptoms.
Interestingly, these kinds of lesions could be related to
some of the DE miRNAs and with the pathways regu-
lated by them. In an artificially induced lung fibrosis in
mice, miR-21 mediates the activation of pulmonary fi-
broblasts [36]. Furthermore, miR-21 has been recently
proposed as an indicator of disease progression and po-
tential treatment target in another mouse model [37].
MiR-21 could control pathways such as the TGF-β1 sig-
naling pathway by targeting SMAD7 and SPRY1 or by
inhibiting PTEN, which is a known negative regulator of
lung fibrosis [38]. The remodelling of lung tissues caused
by fibrosis related hypoxia has also been linked with
miR-21 [39]. Importantly, PTEN has a crucial role in
controlling the PI3K-Akt pathway, and its interaction
with miR-21 has been experimentally validated several
times in human and in mice [40]. The upregulated
miR-148a also targets PTEN, as well as GADD45A and
BCL2L11, and it accelerates the development of auto-
immunity [41].
Another miRNA, miR-99a, which was downregulated
in the diseased sheep, appears to target AKT1 [42]
(which has an important role in the PI3K-Akt pathway)
and inhibits cancer cell proliferation by targeting mTOR
[43]. Thus, its downregulation in the animals with le-
sions should increase AKT1 and mTOR expression,
stimulating proliferative signal. In our analysis,
inflammation-related interleukin 13 (IL-13) was pre-
dicted as a target of miR-98-5p and let-7 family miR-
NAs, and it is noteworthy that previous experimental
observations have shown that let-7 miRNAs can modu-
late inflammation through inhibition of IL-13 [44]. Dur-
ing bluetongue virus infection in sheep testicular cells,
while IL-13 and let-7f were downregulated, let-7d was
upregulated and PI3K-Akt pathway was overrepresented
in the enrichment test of the DE genes [45].
The relationship between the dysregulation of some
miRNAs and VM disease could be a direct consequence
of virus modulation or a side effect of the host defense
mechanisms. In the case of miR-21, it has been proposed
as a key switch in the inflammatory response [40]. Clin-
ical lesions observed could be a consequence of exces-
sive cell survival signalling after the initial proinflam
matory immune response. On the other hand, the virus
itself may modulate miRNA expression, as it does in
EBV and HCV infections [28, 46], during which the vi-
ruses induce miR-21 expression to promote their repli-
cation by enhancing the growth and survival of the
infected cells, thus modulating the response in favour of
the virus. Furthermore, PRRSV downregulated miR-125b
to negatively regulate NF-κB signaling as a survival strat-
egy [47].
Direct targeting of viruses remains controversial not
only because of viral genome structure and rapid evolu-
tion but also because the normal concentrations of miR-
NAs are too low for efficient silencing [48]. Only some
highly expressed DE miRNAs have been analyzed to de-
termine if they could potentially silence some viral RNA.
Interestingly, there were some predicted miRNA target
sites in the SRLV genome, including one for
oar-miR-200a. oar-miR-200a was upregulated in the
lesions-seronegative comparison and could actively tar-
get the viral gag gene in the A genotype. Functional ex-
periments are necessary to uncover the antiviral
functions of these candidate miRNAs.
Conclusions
In this work, we performed for the first time a miRNA
profiling in sheep responding to SRLV infection. Twelve
completely novel miRNA molecules and more than 40
others were found for the first time in sheep. MiRNAs
differentially regulated between seronegative and in-
fected sheep, such as oar-miR-21, oar-miR-148a or
oar-let-7f may have potential implications for the
host-virus interaction. The miRNAs were predicted to
target important genes involved in apoptosis, prolifera-
tion and growth, e.g., the PI3K-Akt and AMPK path-
ways. The role of oar-miR-21 as a regulator of
inflammation and proliferation appeared as a possible
cause for the lesions caused in sheep lungs, and this
miRNA could be an indicator of the severity of the lung
lesions or may be useful as a putative target for thera-
peutic intervention.
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